- Contract Awards
The Biomedical Advanced Research and Development Authority has awarded Emergent BioSolutions (NYSE: EBS) a potential $21.9 million task order to develop and produce a vaccine against Zika virus for use in the first phase of a clinical trial. The company said Monday the order has a base period of 30 months worth $17.9 million and covers...


